Is due:
- Suda Pharmaceuticals Ltd (SUD) and Sanofi-Aventis Groupe have reached an agreement to conduct a feasibility study
- The study will investigate the feasibility of using one of Sanofi's active ingredients in Suda's OroMist Technology
- This technology sprays a drug into the patients mouth, a method which increases absorbtion
- Suda will carry out the fully-funded feasibility study by the end of March, 2021
- Shares in Suda are unchanged, worth 6.6 cents apiece
The Sanofi Deal
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
0.015(11.1%) |
Mkt cap ! $157.7M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 15.0¢ | 14.0¢ | $106.6K | 736.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 487932 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 50000 | 1 |
View Market Depth
| Last trade - 15.36pm 16/08/2024 (20 minute delay) ? |
| ALA (ASX) Chart |